ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
The American College of Cardiology offers select interviews and summaries of cardiology’s most interesting research areas from ACCEL’s renowned library, hosted by ACCEL Editor-in-Chief Alison L. Bailey, MD, FACC, FAACPVR.
info_outline
Top Takeaways from 2025: Preventive Cardiology with C. Noel Bairey Merz, MD, MACC
12/18/2025
Top Takeaways from 2025: Preventive Cardiology with C. Noel Bairey Merz, MD, MACC
In this interview, C. Noel Bairey Merz MD, MACC and Alison L. Bailey, MD FACC, discuss the Top Preventive Cardiology Takeaways from 2025 including trials clopidogrel versus aspirin, the benefit of vaccines, statin use in pregnancy, and more. Suggested Materials: Valgimigli M, Choi KH, Giacoppo D, et al. Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis. Lancet. 2025;406(10508):1091-1102. doi:10.1016/S0140-6736(25)01562-4 O’Leary K. Influenza vaccination benefits patients with heart failure. Nature Medicine. 2025. doi: Christensen JJ, Holven KB, Bogsrud MP, et al. Statin use in pregnancy and risk of congenital malformations: a Norwegian nationwide study. Eur Heart J. Published online August 21, 2025. doi:10.1093/eurheartj/ehaf592 Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025;33(8):1475-1503. doi:10.1002/oby.24336 Brett AS. New Variations on GLP-1–Receptor Agonists are Coming (NEJM/Clinician website). 2025. Available at: . Accessed 12/17/25. Podcasts |
/episode/index/show/accelaccorg/id/39454165
info_outline
Top Takeaways from 2025: EP with DJ Lakkireddy, MBBS, FACC
12/17/2025
Top Takeaways from 2025: EP with DJ Lakkireddy, MBBS, FACC
In this interview, DJ Lakkireddy, MBBS, FACC and Alison L. Bailey, MD FACC, discuss the Top Electrophysiology Takeaways from 2025 including trials CLOSURE-AF, ALONE-AF, NEMESIS-PFA, and more. Suggested Materials: 1. Verma A, Birnie DH, Jiang C, et al. Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. N Engl J Med. Published online November 8, 2025. doi:10.1056/NEJMoa2509688 2. Landmesser U, Skurk C, Kirchhof P, et al. Catheter-based left atrial appendage CLOSURE in patients with atrial fibrillation at high risk of stroke and bleeding as compared to best medical therapy: Rationale and design of the prospective randomized CLOSURE-AF trial. Am Heart J. Published online September 12, 2025. doi:10.1016/j.ahj.2025.09.005 3. Kim D, Shim J, Choi EK, et al. Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial. JAMA. 2025;334(14):1246-1254. doi:10.1001/jama.2025.14679 4. Lakkireddy D, Katapadi A, Garg J, et al. NEMESIS-PFA: Investigating Collateral Tissue Injury Associated With Pulsed Field Ablation. JACC Clin Electrophysiol. 2025;11(8):1747-1756. doi:10.1016/j.jacep.2025.04.017 5. Wazni OM, Saliba WI, Nair DG, et al. Left Atrial Appendage Closure after Ablation for Atrial Fibrillation. N Engl J Med. 2025;392(13):1277-1287. doi:10.1056/NEJMoa2408308 Podcasts |
/episode/index/show/accelaccorg/id/39442960
info_outline
Multimodality Imaging in Inflammatory Cardiomyopathy
12/16/2025
Multimodality Imaging in Inflammatory Cardiomyopathy
Multimodality imaging plays a pivotal role in evaluating inflammatory cardiomyopathy, particularly when cardiac sarcoidosis (CS) is suspected. Symptoms of CS include unexplained high-grade AV block, ventricular arrhythmias, reduced left ventricular function, or regional wall thinning without coronary disease. The best evaluation combines cardiac magnetic resonance imaging (MRI) for structural and scar assessment with fluorodeoxyglucose (FDG)-positron emission tomography (PET) for detecting active inflammation and extracardiac involvement. In this interview, Michelle Kittleson MD, FACC and Ron Blankstein, MD, FACC discuss “Multimodality Imaging in Inflammatory Cardiomyopathy.” Podcasts |
/episode/index/show/accelaccorg/id/39410225
info_outline
Top Takeaways from 2025: Clinical Cardiology with Allen J. Taylor, MD, FACC
12/11/2025
Top Takeaways from 2025: Clinical Cardiology with Allen J. Taylor, MD, FACC
In this interview, Allen J. Taylor, MD, FACC and Alison L. Bailey, MD FACC, discuss the Top Clinical Cardiology Takeaways from 2025 including trials SCOT-HEART 2, ALONE-AF, Launch-HTN, and more. Suggested Materials: 1. Kim D, Shim J, Choi EK, et al. Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial. JAMA. 2025;334(14):1246-1254. doi:10.1001/jama.2025.14679 2. Lemesle G, Didier R, Steg PG, et al. Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. N Engl J Med. 2025;393(16):1578-1588. doi:10.1056/NEJMoa2507532 3. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027 4. Flack JM, Azizi M, Brown JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025;393(14):1363-1374. doi:10.1056/NEJMoa2507109 5. Saxena M, Laffin L, Borghi C, et al. Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial. JAMA. 2025;334(5):409-418. doi:10.1001/jama.2025.9413 6. McDermott M, Khaing PH, Meah MN, et al. CT Angiography, Healthy Lifestyle Behaviors, and Preventive Therapy: A Nested Substudy of the SCOT-HEART 2 Randomized Clinical Trial. JAMA Cardiol. 2025;10(8):841-850. doi:10.1001/jamacardio.2025.1763 Podcasts |
/episode/index/show/accelaccorg/id/39330250
info_outline
Top Takeaways from 2025: Interventional Cardiology with Deepak Bhatt, MD, MPH, MBA, FACC
12/10/2025
Top Takeaways from 2025: Interventional Cardiology with Deepak Bhatt, MD, MPH, MBA, FACC
In this interview, Deepak Bhatt, MD, MPH, FACC and Alison L. Bailey, MD FACC, discuss the Top Interventional Cardiology Takeaways from 2025 including DanGer Shock trial, revascularization in STEMI, aspirin withdrawal after PCI, and more. Suggested Materials: 1. Møller JE, Beske RP, Engstrøm T, et al. Long-Term Outcomes of the DanGer Shock Trial. N Engl J Med. 2025;393(10):1037-1038. doi:10.1056/NEJMc2508284 2. Ueyama HA, Akita K, Kiyohara Y, et al. Optimal Strategy for Complete Revascularization in ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A Network Meta-Analysis. J Am Coll Cardiol. 2025;85(1):19-38. doi:10.1016/j.jacc.2024.09.1231 3. Généreux P, Schwartz A, Oldemeyer JB, et al. Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis. N Engl J Med. 2025;392(3):217-227. doi:10.1056/NEJMoa2405880 4. Guimarães PO, Franken M, Tavares CAM, et al. Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. N Engl J Med. Published online August 31, 2025. doi:10.1056/NEJMoa2507980 5. Valgimigli M, Choi KH, Giacoppo D, et al. Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis. Lancet. 2025;406(10508):1091-1102. doi:10.1016/S0140-6736(25)01562-4 Podcasts |
/episode/index/show/accelaccorg/id/39328435
info_outline
PANTHER-P2Y12 Inhibitor or Aspirin moNoTHERapy as Secondary Prevention in Patients with CAD
12/09/2025
PANTHER-P2Y12 Inhibitor or Aspirin moNoTHERapy as Secondary Prevention in Patients with CAD
he PANTHER study indicates that clopidogrel provides superior protection against major cardiovascular events compared to aspirin in patients with coronary artery disease, without increasing bleeding risk. This supports its use in individuals at higher risk of gastrointestinal complications, reinforcing current clinical preferences. Overall, these results could inform long-term treatment strategies and improve outcomes for millions of patients worldwide. In this interview, Alison L. Bailey, MD, FACC and Prof. Marco Valgimigli discuss “PANTHER-P2Y12 Inhibitor or Aspirin moNoTHERapy as Secondary Prevention in Patients with CAD”. Suggested Materials: 1. Giacoppo D, Gragnano F, Watanabe H, et al. P2Y12 inhibitor or aspirin after percutaneous coronary intervention: individual patient data meta-analysis of randomised clinical trials. BMJ. 2025;389:e082561. Published 2025 Jun 4. doi:10.1136/bmj-2024-082561 2. Valgimigli M, Hong SJ, Gragnano F, et al. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials. Lancet. 2024;404(10456):937-948. doi:10.1016/S0140-6736(24)01616-7 3. P2Y(12) Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, Pettersen AR, Zhao Q, Woodward M, Chiarito M, McFadden EP, Park KW, Kastrati A, Seljeflot I, Zhu Y, Windecker S, Kang J, Schunkert H, Arnesen H, Bhatt DL, Steg PG, Calabrò P, Pocock S, Mehran R, Valgimigli M; PANTHER Collaboration. J Am Coll Cardiol. 2023;82(2):89-105. doi: 10.1016/j.jacc.2023.04.051 Podcasts |
/episode/index/show/accelaccorg/id/39327660
info_outline
ACCEL Lite: Top Takeaways from 2025: HF with Clyde Yancy MD, MSc, MACC
12/04/2025
ACCEL Lite: Top Takeaways from 2025: HF with Clyde Yancy MD, MSc, MACC
In this interview, Clyde Yancy MD, MSc, MACC and Alison L. Bailey, MD FACC, discuss the Top Heart Failure Takeaways from 2025 including trials SUMMIT and BaxHTN, the ACC/AHA Blood Pressure Guidelines, and more. Suggested Materials: 1. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;86(18):1567-1678. doi:10.1016/j.jacc.2025.05.007 2. Khan SS, Coresh J, Pencina MJ, et al. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation. 2023;148(24):1982-2004. doi:10.1161/CIR.0000000000001191 3. Yancy CW. Heart Failure: A Century View, From Failure to Function. Circulation. 2025;151(9):585-588. doi:10.1161/CIRCULATIONAHA.124.072249 4. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027 5. Flack JM, Azizi M, Brown JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025;393(14):1363-1374. doi:10.1056/NEJMoa2507109 Podcasts |
/episode/index/show/accelaccorg/id/39236345
info_outline
ACCEL Lite: Top Takeaways from 2025: CV Imaging with Amit R. Patel, MD, FACC
12/03/2025
ACCEL Lite: Top Takeaways from 2025: CV Imaging with Amit R. Patel, MD, FACC
In this interview, Amit R. Patel, MD, FACC and Alison L. Bailey, MD FACC, discuss the Top Cardiovascular Imaging Takeaways from 2025 including myocardial fibroblast activation, photon-counting detector CT, the newly published ACC/AHA CT Advanced Training Statement, and more. Suggested Materials: 1. Nijveldt R, Maeng M, Beijnink CWH, et al. Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction. N Engl J Med. Published online October 28, 2025. doi:10.1056/NEJMoa2512918 2. Barton AK, Craig NJ, Loganath K, et al. Myocardial Fibroblast Activation After Acute Myocardial Infarction: A Positron Emission Tomography and Magnetic Resonance Study. J Am Coll Cardiol. 2025;85(6):578-591. doi:10.1016/j.jacc.2024.10.103 3. Sakai K, Shin D, Singh M, et al. Diagnostic Performance and Clinical Impact of Photon-Counting Detector Computed Tomography in Coronary Artery Disease. J Am Coll Cardiol. 2025;85(4):339-348. doi:10.1016/j.jacc.2024.10.069 4. Baldassarre LA, Mendes LA, Blankstein R, et al. 2025 ACC/AHA/ASE/ASNC/SCCT/SCMR Advanced Training Statement on Advanced Cardiovascular Imaging: A Report of the ACC Competency Management Committee. J Am Coll Cardiol. Published online November 18, 2025. doi:10.1016/j.jacc.2025.07.036 5. Sahashi Y, Ieki H, Yuan V, et al. Artificial Intelligence Automation of Echocardiographic Measurements. J Am Coll Cardiol. 2025;86(13):964-978. doi:10.1016/j.jacc.2025.07.053 Podcasts |
/episode/index/show/accelaccorg/id/39236190
info_outline
C-Reactive Protein and CV Risk in the General Population
12/02/2025
C-Reactive Protein and CV Risk in the General Population
Inflammation is a key contributor to cardiovascular disease (CVD), influencing both its onset and progression. High-sensitivity C-reactive protein (hsCRP) serves as a reliable biomarker for detecting systemic inflammation and assessing cardiovascular risk. Recognizing the role of inflammation helps refine risk stratification and guide preventive strategies in the general population. In this interview, Nanette Kass Wenger MD, MACC and Prof. Dr. Florian Kahles, MD discuss “C-Reactive Protein and CV Risk in the General Population”. SUGGESTED MATERIALS: Amezcua-Castillo E, González-Pacheco H, Sáenz-San Martín A, et al. C-Reactive Protein: The Quintessential Marker of Systemic Inflammation in Coronary Artery Disease-Advancing toward Precision Medicine. Biomedicines. 2023;11(9):2444. Published 2023 Sep 2. doi:10.3390/biomedicines11092444 Podcasts |
/episode/index/show/accelaccorg/id/39222405
info_outline
ALONE-AF: Discontinuing Long-Term Oral Anticoagulation After Successful AFib Ablation
11/25/2025
ALONE-AF: Discontinuing Long-Term Oral Anticoagulation After Successful AFib Ablation
The ALONE-AF study examined outcomes in atrial fibrillation (AF) patients who remained free of recurrence following catheter ablation. Researchers found that discontinuing oral anticoagulation (OAC) was associated with a lower risk of stroke, systemic embolism, or major bleeding compared to continued OAC. These findings, presented at the ESC Congress 2025, suggest that stopping OAC may offer a safer long-term strategy for select post-ablation AF patients. This could mark a meaningful shift in how clinicians approach anticoagulation management in this population. In this interview, Dhanunjaya “DJ” Lakkireddy MBBS, FACC and Boyoung Joung, MD, PhD discuss “ALONE-AF: Discontinuing Long-Term Oral Anticoagulation After Successful AFib Ablation”. SUGGESTED MATERIALS: New data on oral anticoagulation after successful ablation of atrial fibrillation (escardio.org website). 2025. Available at: . Accessed 11/9/25. Podcasts |
/episode/index/show/accelaccorg/id/39150200
info_outline
How Does Imaging Guide Management in Patients with Obesity?
11/18/2025
How Does Imaging Guide Management in Patients with Obesity?
Imaging is a powerful tool in managing obesity, helping clinicians visualize fat distribution and detect complications like fatty liver disease or heart issues. Advanced techniques like magnetic resonance imaging (MRI) and computed tomography (CT) scans guide personalized treatment plans and monitor progress over time. Despite challenges with equipment limitations, innovations like artificial intelligence and specialized scanners are making imaging more accessible and accurate for patients with obesity. In this interview, W. Douglas Weaver MD, MACC and Mouaz H. Al-Mallah, MD, FACC discuss “How Does Imaging Guide Management in Patients with Obesity?” Podcasts
/episode/index/show/accelaccorg/id/39066930
info_outline
TACSI Trial: Dual or Single Antiplatelet Therapy After CABG in Patients With ACS
11/11/2025
TACSI Trial: Dual or Single Antiplatelet Therapy After CABG in Patients With ACS
In the TACSI trial, researchers evaluated ticagrelor plus aspirin versus aspirin alone in about 2,200 patients who underwent coronary artery bypass grafting (CABG) for acute coronary syndrome (ACS). At 12 months, dual antiplatelet therapy (DAPT) did not reduce major adverse cardiac events compared to aspirin alone. However, it was associated with a higher risk of major bleeding. These findings do not support routine DAPT use post-CABG in ACS patients, though longer-term follow-up is still needed. In this interview, Drs. Steven E. Nissen and Anders Jeppsson discuss “TACSI Trial: Dual or Single Antiplatelet Therapy After CABG in Patients With ACS”. SUGGESTED MATERIALS: Jeppsson A, James S, Moller CH, et al. Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome. N Engl J Med. Published online September 1, 2025. doi:10.1056/NEJMoa2508026 TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome: Reported from ESC Congress 2025 (PCRonline website). 2025. Available at: . Accessed 10/31/25.
/episode/index/show/accelaccorg/id/38982405
info_outline
VICTORION-Difference: Inclisiran-Based Strategy vs. Standard of Care
11/04/2025
VICTORION-Difference: Inclisiran-Based Strategy vs. Standard of Care
Current clinical challenges in lipid control include achieving and maintaining target LDL-cholesterol levels in patients at high risk for atherosclerotic cardiovascular disease, especially those who do not respond adequately to standard therapies. The VICTORION-Difference trial demonstrated that an inclisiran-based treatment strategy significantly outperformed usual care in helping patients reach early and sustained LDL-C goals. This approach also resulted in fewer muscle-related side effects, a common barrier to adherence. Inclisiran offers a convenient, effective, and well-tolerated option for improving lipid management in these patients. In this interview, Drs. Kim A. Williams and Ulf Landmesser discuss “VICTORION-Difference: Inclisiran-Based Strategy vs. Standard of Care.”
/episode/index/show/accelaccorg/id/38896650
info_outline
Aortopathies: What A Cardiologist Needs to Know
10/28/2025
Aortopathies: What A Cardiologist Needs to Know
What if your genes could predict a life-threatening condition before symptoms ever appear? Explore how medical science uncovered the genetic roots of thoracic aortic aneurysm—and why that discovery changed everything. From famous historical figures to modern patients, the implications are profound: understanding the exact genetic mutation can guide treatment and safeguard entire families. In this interview, Drs. Jeroen J. Bax and John A. Elefteriades discuss “Aortopathies: What A Cardiologist Needs to Know”.
/episode/index/show/accelaccorg/id/38795610
info_outline
PhysioSync-HF: Conduction System vs. Biventricular Pacing in Cardiac Resynchronization in HFrEF
10/21/2025
PhysioSync-HF: Conduction System vs. Biventricular Pacing in Cardiac Resynchronization in HFrEF
Can a newer, more targeted pacing method revolutionize heart failure treatment? The PhysioSync-HF trial investigates conduction system pacing as a potentially more effective and affordable alternative to traditional cardiac resynchronization therapy. Explore the surprising differences between this study and prior research and hear firsthand what it was like to lead a nationwide, publicly funded clinical trial across Brazil. This episode dives deep into innovation, equity, and the future of heart care. In this interview, Drs. Joseph Marine and André Zimerman discuss “PhysioSync-HF: Conduction System vs. Biventricular Pacing in Cardiac Resynchronization in HFrEF”.
/episode/index/show/accelaccorg/id/38646840
info_outline
DAPT-SHOCK-AMI Trial: Cangrelor in Cardiogenic Shock
10/14/2025
DAPT-SHOCK-AMI Trial: Cangrelor in Cardiogenic Shock
The DAPT SHOCK AMI trial is the first major study to evaluate antiplatelet therapy specifically in patients with cardiogenic shock (CS) following acute myocardial infarction (AMI). It compares initial treatment strategies using cangrelor versus crushed ticagrelor. Early and potent platelet inhibition is critical for restoring microvascular reperfusion in this high-risk population. Previous randomized trials have excluded these patients, leaving a gap in evidence for optimal antiplatelet management in AMI-CS. In this interview, Drs. Dipti Itchhaporia and Zuzana Motovska discuss “DAPT-SHOCK-AMI Trial: Cangrelor in Cardiogenic Shock”.
/episode/index/show/accelaccorg/id/38578380
info_outline
ODYSSEY-HCM: Mavacamten in nHCM
10/07/2025
ODYSSEY-HCM: Mavacamten in nHCM
The ODYSSEY-HCM trial found that mavacamten did not significantly improve exercise capacity or patient-reported outcomes in individuals with symptomatic nonobstructive hypertrophic cardiomyopathy. Safety concerns emerged, including more frequent reductions in ejection fraction and treatment interruptions among those receiving mavacamten. The trial's limited diversity and short duration raise questions about the generalizability and long-term implications of the findings. Despite the lack of approved therapies for this patient group, the study underscores the complexity of using surrogate endpoints and the need for deeper exploration into disease mechanisms and treatment response. In this interview, Matthew Martinez MD, FACC and Milind Y. Desai, MD, MBA, FACC discuss “ODYSSEY-HCM: Mavacamten in nHCM.” Podcasts |
/episode/index/show/accelaccorg/id/38429985
info_outline
DAN-RSV: RSVpreF Vaccine for Preventing Cardiorespiratory Hospitalizations
09/30/2025
DAN-RSV: RSVpreF Vaccine for Preventing Cardiorespiratory Hospitalizations
The DAN-RSV trial is one of the largest individually randomized studies ever conducted, enrolling over 131,000 participants aged 60 and older to evaluate the effectiveness of the RSVpreF vaccine. Using a pragmatic design with electronic consent and national health registry data, the trial successfully met its primary objective of reducing RSV-related respiratory tract disease hospitalizations. It also achieved all key secondary endpoints, showing favorable outcomes for RSV-related and all-cause respiratory and cardiorespiratory hospitalizations. These results demonstrate the vaccine’s potential to significantly impact public health and inform future RSV vaccine policy. In this interview, Drs. Richard A. Chazal and Tor Biering-Sørensen discuss “DAN-RSV: RSVpreF Vaccine for Preventing Cardiorespiratory Hospitalizations.” Suggested Materials: Tor Biering-Sørensen (2025). Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Older Adults (DAN-RSV) (ClinicalTrials.gov Identifier NCT06684743). Retrieved from . Podcasts |
/episode/index/show/accelaccorg/id/38366860
info_outline
The Role of Prevention During and After Reproduction
09/23/2025
The Role of Prevention During and After Reproduction
Adverse pregnancy outcomes (APOs), affecting up to 20% of pregnancies, serve as early indicators of a woman’s future cardiovascular risk and should be treated as critical markers in preventive care. Pregnancy offers a unique opportunity—a “window”—to identify and address cardiovascular vulnerabilities, making routine screening for heart health essential at every clinical encounter. Long-term monitoring beyond the postpartum period is vital, as cardiovascular risks persist and evolve over time. Improving women’s heart health requires a collaborative, lifelong approach across specialties, integrating cardiology with obstetrics and primary care. This comprehensive strategy ensures that prevention remains central during and after reproduction. In this interview, Drs. Alison L. Bailey, MD, FACC and Ijeoma Isiadinso, MD, FACC discuss “The Role of Prevention During & After Reproduction”. Podcasts |
/episode/index/show/accelaccorg/id/38252320
info_outline
The Role of Imaging in Cardiovascular Prevention
09/16/2025
The Role of Imaging in Cardiovascular Prevention
Cohort studies have provided robust data on cardiovascular risk factors, forming the basis for predictive models like the Pooled Cohort Equations and PREVENT. Clinical trials confirm that treating these risk factors effectively reduces cardiovascular events. Over the past 50 years, age-adjusted mortality from acute myocardial infarction has dropped by 89%, reflecting major progress. To advance further, we must consider integrating imaging to identify those at highest risk, using risk factors to guide treatment decisions. This dual approach could enhance precision and improve outcomes in cardiovascular prevention. In this interview, Drs. Alison L. Bailey and David J. Maron discuss “The Role of Imaging in Cardiovascular Prevention”.
/episode/index/show/accelaccorg/id/38222820
info_outline
Improving Cardiovascular Clinical Competencies Menopausal Transition
09/09/2025
Improving Cardiovascular Clinical Competencies Menopausal Transition
The menopause transition marks a pivotal period of cardiometabolic change that significantly elevates cardiovascular (CV) risk in women. Despite its clinical importance, this phase remains underrecognized in CV risk assessment, contributing to a profound knowledge gap. Enhancing clinician education and fostering multidisciplinary collaboration are essential to delivering individualized care that addresses both symptom burden and long-term CV outcomes. By prioritizing this life stage, we can improve prevention strategies and reduce the overall burden of cardiovascular disease in women. In this interview, Drs. Alison L. Bailey and Lily Dastmalchi discuss “Improving Cardiovascular Clinical Competencies for Menopausal Transition”. Podcasts |
/episode/index/show/accelaccorg/id/38136730
info_outline
Behind the 2025 ACC/AHA Acute Coronary Syndrome Guideline
09/02/2025
Behind the 2025 ACC/AHA Acute Coronary Syndrome Guideline
The 2025 ACC/AHA Acute Coronary Syndrome guideline is the first major update since 2013, incorporating a decade of new evidence and clinical insights. The writing committee stayed on track and on time, reaching consensus on key recommendations, including checklist-based Class I and II interventions before discharge. They thoughtfully addressed legacy practices and controversial studies to ensure clarity and relevance. While some emerging data didn’t meet the threshold for formal inclusion, areas like discharge antiplatelet therapy, coronary imaging, and mechanical support devices were flagged as important for clinicians to monitor. The result is a practical, evidence-based tool to guide bedside decision-making. In this interview, Drs. Roxana Mehran and Sunil V. Rao take listeners “Behind the 2025 Acute Coronary Syndrome Guidelines.” Podcasts |
/episode/index/show/accelaccorg/id/38056645
info_outline
Top Takeaways From the 2025 ACC/AHA Acute Coronary Syndrome Guideline
08/26/2025
Top Takeaways From the 2025 ACC/AHA Acute Coronary Syndrome Guideline
The 2025 ACC/AHA Acute Coronary Syndrome (ACS) Guideline clarifies diagnostic distinctions using electrocardiogram changes, troponin levels, and imaging tools such as coronary CT angiography and echocardiography in the emergency setting. Updates in lipid-lowering strategies and antiplatelet therapy reflect a more personalized approach to risk reduction and long-term care. These recommendations aim to streamline acute decision-making and improve outcomes across the ACS spectrum. In this interview, Drs. Sidney C. Smith Jr. and Michelle L. O'Donoghue discuss “Top Takeaways From the 2025 ACC/AHA Acute Coronary Syndrome Guideline.” Podcasts | |
/episode/index/show/accelaccorg/id/37947920
info_outline
Risk vs. Benefit in Chronic Total Occlusion Revascularization
08/19/2025
Risk vs. Benefit in Chronic Total Occlusion Revascularization
Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI) is a procedure used to open coronary arteries that have been completely blocked for an extended period. It offers benefits like reduced angina and improved quality of life but carries risks such as vessel injury, heart attack, and procedural failure. Before considering CTO PCI, physicians typically optimize patients on anti-anginal medications—such as beta-blockers, nitrates, and calcium channel blockers—to manage symptoms and evaluate the need for intervention. In this interview, Drs. Anthony N. DeMaria and Lindsey Cilia examine “Risk versus Benefit in Chronic Total Occlusion Revascularization.” Podcasts |
/episode/index/show/accelaccorg/id/37864360
info_outline
LAAO vs. DOAC for Stroke Prevention in AFib
08/12/2025
LAAO vs. DOAC for Stroke Prevention in AFib
While blood thinners like warfarin and direct oral anticoagulants (DOACs) remain the standard for stroke prophylaxis, left atrial appendage occlusion (LAAO) devices offer a non-pharmacologic alternative for patients at high bleeding risk. Recent trials have shown that LAAO can be as effective as anticoagulants in preventing stroke and may be a viable option, especially for patients who cannot tolerate long-term anticoagulation. In this interview, Drs. Anthony N. DeMaria and Dhanunjaya Lakkireddy explore the evolving landscape of stroke prevention in patients with atrial fibrillation, focusing on the comparison between traditional blood thinners and LAAO. Podcasts |
/episode/index/show/accelaccorg/id/37764960
info_outline
Why Are They Still Dyspneic? Post PE Syndrome Workup and Management
08/05/2025
Why Are They Still Dyspneic? Post PE Syndrome Workup and Management
Persistent symptoms after an acute pulmonary embolism (PE) may indicate post-pulmonary embolism syndrome (PPES), a condition affecting up to 50% of patients. The most important consideration in managing PPES is to carefully evaluate and differentiate it from other potential causes of ongoing shortness of breath, particularly chronic thromboembolic pulmonary hypertension (CTEPH), which requires targeted treatment. How can clinicians best differentiate between PPES and other causes of persistent symptoms following an acute PE? In this interview, Drs. Dipti Itchhaporia and Paul R. Forfia discuss “Why Are They Still Dyspneic? Post PE Syndrome Workup and Management.” Podcasts|
/episode/index/show/accelaccorg/id/37662875
info_outline
Palliative Care Across the Spectrum of Biological Age in Heart Failure
07/29/2025
Palliative Care Across the Spectrum of Biological Age in Heart Failure
Palliative care supports heart failure patients by guiding complex medical decisions, managing symptoms, and enhancing quality of life. Despite being a guideline-recommended therapy, it remains underused—referrals are 45% lower for heart failure patients than for cancer patients with similar prognoses. Collaboration between cardiology and palliative care teams ensures that patients and caregivers receive goal-aligned care and the best possible quality of life. In this interview, Dr. Mary Norine Walsh and Ms. Jill A. Patton explore how palliative care can help patients across the span of their illness. Related References: 1. Chuzi S, Saylor MA, Allen LA, et al. Integration of Palliative Care into Heart Failure Care: Consensus-Based Recommendations from the Heart Failure Society of America. J Card Fail. 2025;31(3):559-573. doi:10.1016/j.cardfail.2024.10.435 2. Gelfman LP, Blum M, Ogunniyi MO, McIlvennan CK, Kavalieratos D, Allen LA. Palliative Care Across the Spectrum of Heart Failure. JACC Heart Fail. 2024;12(6):973-989. doi:10.1016/j.jchf.2024.01.010 Podcasts |
/episode/index/show/accelaccorg/id/37577955
info_outline
ACCEL Lite: Hypertension Diagnosis and Management: Renal Denervation and Newer Agents on the Horizon
07/22/2025
ACCEL Lite: Hypertension Diagnosis and Management: Renal Denervation and Newer Agents on the Horizon
Recent clinical trials demonstrate that intensive blood pressure lowering—targeting systolic levels below 120 mm Hg—can significantly reduce cardiovascular events and mortality, even among older adults, individuals with diabetes, and those with chronic kidney disease. This challenges the long-standing belief that looser blood pressure targets are safer for older patients, showing instead that with proper monitoring, tighter control offers substantial net benefits for most high-risk groups. In this interview, Dr. Alison L. Bailey and Dr. Keith C. Ferdinand explore the evolving landscape of hypertension management, highlighting new evidence supporting the benefits of tight blood pressure control across diverse populations. Suggested Materials: 1. Liu J, Li Y, Ge J, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024;404(10449):245-255. doi:10.1016/S0140-6736(24)01028-6 2. Bi Y, Li M, Liu Y, et al. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N Engl J Med. 2025;392(12):1155-1167. doi:10.1056/NEJMoa2412006 3. Reddy TK, Nasser SA, Pulapaka AV, Gistand CM, Ferdinand KC. Tackling the Disproportionate Burden of Resistant Hypertension in US Black Adults. Curr Cardiol Rep. 2024;26(11):1163-1171. doi:10.1007/s11886-024-02115-5 Podcasts |
/episode/index/show/accelaccorg/id/37484370
info_outline
What's the Best Time to Revascularize the Non-culprit Lesions in MVD
07/15/2025
What's the Best Time to Revascularize the Non-culprit Lesions in MVD
Rapid emergency medical services transport to a percutaneous coronary intervention (PCI)-capable hospital is critical for timely intervention and management of life-threatening arrhythmias in ST-elevation myocardial infarction patients. Upon emergency room arrival, immediate transfer to the cath lab is essential to restore perfusion and improve both short- and long-term cardiovascular outcomes, as recommended by clinical guidelines. Interventional cardiologists must also be adept at managing culprit lesions in multivessel disease (MVD) and addressing complications like the no-reflow phenomenon during PCI. In this interview, Drs. Dipti Itchhaporia and Nabil Farag discuss “What's the Best Time to Revascularize the Non-culprit Lesions in MVD.” Suggested Materials: Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes [published correction appears in Eur Heart J. 2024 Apr 1;45(13):1145. doi: 10.1093/eurheartj/ehad870.]. Eur Heart J. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191 Mehta SR, Wood DA, Meeks B, et al. Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarction. Am Heart J. 2019;215:157-166. doi:10.1016/j.ahj.2019.06.006 Podcasts |
/episode/index/show/accelaccorg/id/37399000
info_outline
Putting it All Together: Cardiogenic Shock Management in 2025
07/08/2025
Putting it All Together: Cardiogenic Shock Management in 2025
Cardiogenic shock remains a critical, time-sensitive emergency with a high mortality rate. However, recent advances—particularly multidisciplinary, team-based strategies—have shown promise in improving patient outcomes. With the release of the , clinicians now have access to a streamlined, evidence-informed roadmap for early recognition, rapid stabilization, and escalation of care. In this episode, Drs. Glenn A. Hirsch and Shashank S. Sinha explore the latest strategies in cardiogenic shock management in 2025, emphasizing the how the new guidance integrates clinical decision-making tools and highlighting the role of shock teams and regional partnerships in optimizing care delivery. SUGGESTED MATERIALS: Sinha SS, Geller BJ, Katz JN, et al; American Heart Association Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular and Stroke Nursing; and Council on Kidney in Cardiovascular Disease. Evolution of Critical Care Cardiology: An Update on Structure, Care Delivery, Training, and Research Paradigms: A Scientific Statement From the American Heart Association. Circulation. 2025 Feb 13. doi: 10.1161/CIR.0000000000001300. Epub ahead of print. PMID: 39945062. Hall EJ, Agarwal S, Cullum CM, Sinha SS, Ely EW, Farr MA. Survivorship After Cardiogenic Shock. Circulation. 2025 Jan 21;151(3):257-271. doi: 10.1161/CIRCULATIONAHA.124.068203. Epub 2025 Jan 21. PMID: 39836757. Ton VK, Li S, John K, et al. Serial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report. J Am Coll Cardiol. 2024 Aug 1:S0735-1097(24)07740-4. doi: 10.1016/j.jacc.2024.04.069. Epub ahead of print. PMID: 39217545. Podcasts |
/episode/index/show/accelaccorg/id/37306205